Clinical Trials
-
s Sponsored
Keeping phase I clinical trials running safely during a pandemic
The pandemic has profoundly reshaped life as we know it. Over the past 12 months, many offices largely transitioned to remote working. However, for those conducting phase I clinical trials, this simply wasn’t possible and adaptive measures had to be enforced. After the first lockdown was announced in March 2020, as an organisation, we set...
-
s Sponsored
Patient safety is pivotal in phase I trials
Clinical trials sit at the heart of therapeutic development and new medicines, ensuring they are conducted safely remains paramount. Robust design of phase I clinical trials is critical to ensure patient safety during the process of developing new therapies and drugs. This is particularly important when potential new treatments move into first-in-human studies in phase I before conducting more detailed phase II and phase...
-
s Sponsored
Improving outcomes for neurology clinical trials
Clinical trials in neurological diseases are a complex area of research where figures suggest there is an unusually high failure rate. Data from the United States shows that only 5.9% of phase I neurology clinical trial drugs are likely to get FDA approval and of the 2,352 neurology clinical trials started in 2020, fewer than...
-
Important, expected, and possible… even in a public health emergency
Patients must be involved in the design as well as participation of clinical trials to ensure they are relevant for the people they are created for. At the Health Research Authority, we ask researchers to tell us about the patient and public involvement in their research when they apply to us for regulatory approval of...
-
Ensuring better patient outcomes through decentralised trials
The global COVID-19 pandemic has created a fundamental shift in the way we run clinical trials, this momentum could help change the future of research. The rapid outbreak of COVID-19 presented unprecedented global challenges. The eyes of the world were on our industry as we mobilised to help develop new diagnostics, vaccines and treatments in...
-
Decentralised clinical trials, the future of clinical research
The COVID-19 pandemic has been a catalyst for change which has led us to revisit the way we conduct clinical trials. As a result, there is now a greater variety of approaches with proven value for patients. Traditional clinical research is conducted through the centralisation activities at a clinical trial site such as a physician’s...
-
Tackling treatment uncertainty: why experiments need to show results
During the global pandemic, randomised controlled trials (RCTs) have been essential in identifying effective treatments and vaccines for COVID-19. Early in 2020, as the first COVID-19 patients arrived in hospitals, the medical world collectively faced a new unknown. With so little information available, we relied on the experience, judgement and bravery of countless healthcare professionals...
-
Re-evaluating clinical trials to ensure their effective progress
Strengthening clinical trial capabilities and infrastructure is key to yielding actionable data. The COVID-19 pandemic has posed challenges to the conduct of all clinical trials, including those for COVID-19. To advise investigators during the pandemic, the Food and Drug Administration (FDA) issued guidance on how best to adapt trials, including recommendations on the use of virtual visits and methods for secure delivery of medications. The agency also issued guidance...
-
Why research transparency is everyone’s business
Everyone involved in clinical research has responsibility to ensure it’s open and transparent. Transparency has never been more crucial in research. In March 2020, as the first urgent public health studies began, it became clear that research would be central to our response to the pandemic. As an organisation, we knew that public visibility about...
-
s Sponsored
Rethinking data quality best practice in the era of decentralised clinical trials
Pandemic-related disruptions have accelerated much-needed change in clinical operations, but this change has been accompanied by questions about data collection and data quality. In a recent survey commissioned by Oracle Health Sciences, more than 75% of industry respondents indicated that limitations in patients’ ability to attend on-site visits sped up their adoption of decentralised clinical trial...
Global Cause